Introduction {#Sec1}
============

Vitamin D is widespread in nature and photosynthesized in most plants and animals exposed to sunlight \[[@CR1]\]. Its major role in vertebrate animals and humans is to increase the absorption of calcium and phosphate for mineralization of the skeleton. In vitamin D-deficient children, the cartilage is not calcified, causing rickets. In adults with vitamin D deficiency, the newly formed bone matrix (the osteoid) is not mineralized, causing osteomalacia \[[@CR2]\].

Synthesis of vitamin D takes place in the skin under the effect of sunlight. The Indian subcontinent is situated between 8.4° N and 37.6° N latitude and has adequate sunshine throughout the year. Despite this fact, studies have shown widespread prevalence of hypovitaminosis D that may have an adverse impact on bone health \[[@CR3]--[@CR7]\]. Even frank nutritional osteomalacia has been reported in urban Indians \[[@CR8]\]. Avoidance of sunlight, cultural and clothing practices, and skin pigment are factors contributing to vitamin D deficiency. Increasing urbanization that results in poor outdoor activity and greater pollution may further aggravate the problem \[[@CR9]\].

Severe vitamin D deficiency results in clinically apparent metabolic bone disease, i.e., rickets and osteomalacia. Subclinical vitamin D deficiency or insufficiency can result in decrease in overall bone mass and, therefore, an increased risk of osteoporosis \[[@CR3], [@CR10]\]. Adequate replacement with vitamin D can increase the bone mass and decrease the risk of fractures \[[@CR11]\].

The optimal dose of vitamin D intake for the general population remains a subject of controversy. Experts now feel that 25-hydroxyvitamin D (25(OH)D) level of 30 ng/ml is required for maintaining optimal skeletal health \[[@CR12]\]. Average 25(OH)D levels in Indians have been reported to be between 3 and 10 ng/ml in various studies especially from north India. The recommended doses of vitamin D (200--400 IU/day) intake are grossly inadequate to bring such low 25(OH)D levels to the desired levels \[[@CR13]--[@CR17]\]. This study was, therefore, undertaken to assess the efficacy and safety of cholecalciferol supplementation administered orally, 60,000 and 120,000 IU/month equivalent to 2,000 IU/day (50 μg/day) and 4,000 IU/day (100 μg/day), respectively, in apparently healthy Indian women. This dose was chosen because this preparation is commonly and widely used in Indian setting, and the dose seems to be in agreement with the current suggestions available on vitamin D supplementation in the literature \[[@CR14]\]. According to present studies, a dose as high as 10,000 IU/day is likely to pose no risk of adverse effects \[[@CR18]\].

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Study subjects included 100 apparently healthy adult Indian women of reproductive age group. They were all employees of Indraprastha Apollo Hospital (nurses, doctors, and administrative staff) who volunteered to participate in the study. None of these subjects had clinical signs and symptoms of overt metabolic bone disease such as bone pains, myopathy, or fractures. Study subjects included menstruating women \>18 years of age.

Exclusion criteria included history of renal failure, liver failure, malabsorption disorder, known disorders of parathyroid function, hypercalcemia, hypocalcemia, known history of vitamin D intoxication and granulomatous diseases, and history of drug ingestion known to affect vitamin D metabolism (steroids, phenytoin, carbamazepine, and rifampicin).

Daily intake of dietary calcium was calculated from a food frequency questionnaire. Sunlight exposure was assessed by taking history of duration of daily sunlight exposure.

Study design and conduct {#Sec4}
------------------------

Study subjects were randomized into two groups: group A and group B by simple randomization. They were randomly assigned to receive either vitamin D supplementation with cholecalciferol 60,000 IU/month administered orally or no supplementation in a 1:1 ratio, during the month of March (spring). This randomization was done regardless of their baseline 25(OH)D status. Group B received one sachet of cholecalciferol (containing 1,500 μg/60,000 IU vitamin D~3~, Cadila Pharmaceutical, India) per month, dissolved in a glass of milk, for 3 months. Subjects were made to drink this milk once a month under observation (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Study design

The baseline results showed presence of hypovitaminosis D in all the study subjects (25(OH)D \<20 ng/ml). At 3 months of review by the ethics committee, it was suggested that the study design be modified since it would be unethical to keep the subjects in group A, with significant hypovitaminosis D, deprived of vitamin D. In view of this, after 3 months, group A (low-dose group) received one sachet of cholecalciferol (60,000 IU) and group B (high-dose group) received two sachets of cholecalciferol (120,000 IU) once a month for 6 months. Vitamin D doses are usually described in their daily amounts; we, therefore, express the monthly doses given here in their average daily amounts of 2,000 IU/day (50 μg/day) and 4,000 IU/day (100 μg/day). Blood and urine samples were drawn at 3 months (June, summer) and again at 9 months (December, winter).

Daily dietary intake of calcium was measured by semiquantitative food frequency questionnaire. All subjects were given diet charts that provided 800--1,000 mg of calcium/day. The study protocol including vitamin D supplementation was approved by the ethics committee of our institution, and informed consent was obtained from all the subjects.

Follow-up, compliance, and actual number of subjects analyzed {#Sec5}
-------------------------------------------------------------

At baseline, there were 100 subjects (A---50, B---50). Nine subjects lost follow-up at 3 months (A---42, B---49), and 31 subjects lost follow-up at 9 months (A---32, B---37). The reason for drop out was migration.

Biochemical estimations {#Sec6}
-----------------------

Blood samples were drawn after an overnight fast between 0800 and 1000 hours at 0, 3, and 9 months for calcium, phosphorus, alkaline phosphatase, 25(OH)D, parathyroid hormone (PTH) estimation, and urine samples for calcium, phosphorus, and creatinine estimation. Samples for 25(OH)D and intact PTH were cold-centrifuged for 15 min at 8°C, and serum was stored in plastic aliquots at −20°C. The frozen serum was then transported on dry ice to Sanjay Gandhi Post Graduate Institute, Lucknow, India. Serum 25(OH)D concentrations were estimated by radioimmunoassay (Diasorin, Stillwater, MN 55082-0285, USA; kit, normal range 9.3--37.9 ng/ml). The sensitivity of this assay is 1.5 ng/ml, within-run coefficient of variation (CV) is 10.5%, and the total imprecision CV is 8.2% at 22.7 ng/ml. Vitamin D deficiency, insufficiency, and sufficiency were defined based on serum 25(OH)D concentrations as \<20, 20--30, and \>30 ng/ml, respectively \[[@CR13]--[@CR15]\]. The assays were analyzed in duplicate. Serum intact PTH was measured by using an immunoradiometric assay (Diasorin; 10--55 pg/ml). However, 10--55 pg/ml is the locally determined PTH range used at SGPGI Laboratory, which has been analyzing these tests for several years. Analytical sensitivity of the assay is 0.7 pg/ml. Intra-assay variation is 3.6% at mean value of 26 pg/ml, and inter-assay variation is 3.4% at mean value of 49 pg/ml. Serum total calcium, inorganic phosphorus, and alkaline phosphatase were estimated by colorimetric method using commercial kits.

Statistical analysis {#Sec7}
--------------------

Results are expressed as means ± SDs. Analysis was performed using SPSS software (version 12.0). Group means were compared by using parametric (paired *t* test). Nonparametric test (Wilcoxon-signed ranks test) was used to compare various indices at three different time intervals because the variables did not show normal distribution. A *P* value of \<0.05 was considered significant.

Results {#Sec8}
=======

Baseline characteristics {#Sec9}
------------------------

One hundred healthy volunteers were recruited during the spring month of March 2007. Mean age and body mass index of the females was 26.82 ± 5.14 years and 22.34 ± 3.61 kg/m^2^, respectively. Mean dietary calcium intake was 525 ± 176.53 mg/day. Range for daily calcium intake estimate was 200--1,200 mg/day. Mean daily sunlight exposure was 15 ± 5 min/day. The average body surface area exposed during winters was 10% and during summers 20%. None of the study subjects had any signs and symptoms of vitamin D deficiency.

Mean 25(OH)D was 4.7 ± 3.4 ng/ml and PTH was 50 ± 24 pg/ml. All our subjects had hypovitaminosis D (\<20 ng/ml). Ninety-four percent of the subjects in group A and 90.6% of the subjects in group B had 25(OH)D levels \<10 ng/ml. There were no between-group differences in age, calcium intake, sunlight exposure, and baseline biochemical bone parameters (Table [1](#Tab1){ref-type="table"}). Table 1Comparison of baseline parameters between group A and group BVariableGroup A (control), *N* = 50 (mean ± SD)Group B (supplement), *N* = 50 (mean ± SD)Age (years)26 ± 6.3227 ± 6.16Serum calcium (mg/dl)9.06 ± 0.409.10 ± 0.38Serum phosphorus (mg/dl)3.84 ± 0.554.0 ± 0.60Serum alkaline phosphatase (IU/l)75 ± 2469 ± 22Serum creatinine (mg/dl)0.67 ± 0.110.68 ± 0.1125(OH)D (ng/ml)4.5 ± 3.44.8 ± 3.5PTH (pg/ml)52 ± 2549 ± 24Between-group differences were not significant, *P* \> 0.05

At 3 months follow-up {#Sec10}
---------------------

Blood and urine samples were drawn after 3 months, during the month of June (summer). In group B (high-dose group), serum 25(OH)D levels increased from 4.8 ± 3.5 ng/ml (March) to 31.6 ± 15.5 ng/ml (June), after 3 months of supplementation with 60,000 IU of cholecalciferol per month administered orally (*P* \< 0.001; Fig. [2a](#Fig2){ref-type="fig"}). This statistically significant increase had brought down the percentage of subjects with 25(OH)D \<20 ng/ml from 100% at baseline to 30% after supplementation, and only four subjects (8.2%) had 25(OH)D \<10 ng/ml. The associated decrease in serum intact PTH and serum total alkaline phosphatase level was also significant (*P* \< 0.05). Fig. 2**a** Change in 25(OH)D levels in groups A and B. **b** Change in PTH levels in groups A and B

In group A (low-dose group), increase in serum 25(OH)D levels was also observed, from 4.5 ± 3.4 (March) to 10.8 ± 7.2 ng/ml (June; *P* \< 0.001). This increase was found to be significant (*P* \< 0.001) but was markedly less as compared to that in group B (Fig. [2a](#Fig2){ref-type="fig"}). Ninety percent of the subjects in group A continued to have 25(OH)D \<20 ng/ml. Interestingly, significant decrease in serum intact PTH and serum total alkaline phosphatase level was also observed. There was no significant change observed in other biochemical variables.

After 6 months of supplementation (December) {#Sec11}
--------------------------------------------

At the end of 3 months, group A received 60,000 IU and group B received 120,000 IU of cholecalciferol once a month administered orally for 6 months. Samples were drawn after 6 months during the month of December (winters).

In group A, 25(OH)D levels increased from 10.8 ± 7.2 to 22.4 ± 12.4 ng/ml (*P* \< 0.001) in 6 months (Fig. [2a](#Fig2){ref-type="fig"}). Serum PTH levels declined from 43 ± 22 to 21 ± 9 pg/ml (*P* \< 0.001; Fig. [2b](#Fig2){ref-type="fig"}), and serum calcium levels had increased (*P* = 0.001). Change in other biochemical parameters was not found to be significant. Fifty-five percent of the subjects in group A had 25(OH)D \>20 ng/ml and 9.7% of the subjects had 25(OH)D \<10 ng/ml after 6 months of supplementation with 60,000 IU of cholecalciferol once a month (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Percentage of subjects with 25(OH)D \>20 ng/ml

In group B, 25(OH)D levels did not change after 6 months of supplementation with 120,000 IU of cholecalciferol once a month. Mean 25(OH)D level at 3 months was 31.6 ± 15.5 ng/ml and, at 9 months, was 30.7 ± 12.8 ng/ml (Fig. [2a](#Fig2){ref-type="fig"}). However, the percentage of subjects with 25(OH)D \>20 ng/ml had increased to 82% and only one subject (2.7%) had 25(OH)D \<10 ng/ml (Fig. [3](#Fig3){ref-type="fig"}). Serum PTH levels reduced from 38 ± 16 to 19 ± 8 pg/ml (*P* \< 0.001; Fig. [2b](#Fig2){ref-type="fig"}). Increase in serum calcium was found to be significant in both groups (*P* \< 0.05), although it did not exceed the upper limit of normal in any subject.

Discussion {#Sec12}
==========

The current study evaluates serum 25(OH)D and PTH responses at 3 and 9 months after oral supplementation with cholecalciferol once a month in apparently healthy adult women of reproductive age group. Our data confirm high prevalence of vitamin D deficiency in India, as shown in previous studies \[[@CR3]--[@CR7]\]. This is despite the fact that India is a tropical country with abundant sunshine. The increasing awareness about widespread prevalence of vitamin D deficiency has led to an ongoing debate regarding corrective measures and adequate intake to correct hypovitaminosis D. Based on currently available evidence, serum 25(OH)D level of 30 ng/ml provides several specific health benefits like optimal bone mineral density, improved muscle strength, and reduced risk of fall and fractures \[[@CR12]\]. The recommended daily intake of vitamin D has been close to 10 μg (400 IU/day) until 1997 \[[@CR17]\]. Various studies have shown that this daily allowance is not sufficient \[[@CR14]--[@CR17]\]. To achieve 25(OH)D level of 30 ng/ml, vitamin D supplementation dose needs to be increased to 1,000--4,000 IU/day \[[@CR14], [@CR19], [@CR20]\]. Individuals with abundant sunlight exposure can easily exhibit a serum 25(OH)D \>60 ng/ml which would be a physiologic supplement input of vitamin D intake \>100 μg (4,000 IU/day). Concerns about safety of vitamin D when used in "higher" doses have been largely dispelled with recent evidence that a prolonged intake of even 250 μg (10,000 IU/day) of vitamin D~3~ is likely to pose no risk of adverse effects \[[@CR18]\].

This study evaluates the response to different monthly doses of vitamin D. The study was carried out in New Delhi (location---28.38° N, 77.12° E). This city experiences marked seasonal variations: spring---February to March, summer---April to June, and winter---November to January. The zenith angle is 84.5° in peak summer and 38.5° in peak winter.

Our results showed that 60,000 IU/month (2,000 IU/day) of cholecalciferol supplementation administered orally for 3 months during summer increased 25(OH)D levels dramatically to near normal levels in group B (4.8 ± 3.5 to 31.6 ± 15.5 ng/ml). A similar increase (5.4 ± 3.0 to 33 ± 20.7 ng/ml) was demonstrated in an Indian study by Goswami et al. \[[@CR24]\]. However, the supplementation dose used in their study was higher, 1,500 μg (60,000 IU) of cholecalciferol per week (8,000 IU/day). This supplementation was given for a period of 2 months and evaluation was done during winter months. Their study further showed that these 25(OH)D levels again declined to suboptimal levels, 1 year after discontinuation of vitamin D supplementation. In another study by Veith et al. \[[@CR22]\], 25(OH)D levels increased effectively to high-normal concentrations in practically all adults, and serum 25(OH)D levels remained within the physiologic range following supplementation with 100 μg (4,000 IU/day) of cholecalciferol for 6 months.

The study subjects in group A, who did not receive any supplementation, also showed increase in 25(OH)D levels (4.5 ± 3.4 to 10.8 ± 7.2 ng/ml) at 3 months. This was most likely due to the effect of seasonal variation on 25(OH)D levels since the initial samples were drawn in March (spring), and the 3-month samples were drawn in June (summer; zenith angle is 84.5° in peak summer). Sunlight exposure during summer is more effective in raising 25(OH)D levels \[[@CR23]\]. This was also evident in an earlier study from India which showed higher 25(OH)D concentrations in summer (7.1 ng/ml) than in winters (3.1 ng/ml) \[[@CR21]\]. However, the effect of supplementation in group B was more marked as compared to the effect of season in both groups (*P* \< 0.05; Table [2](#Tab2){ref-type="table"}). Table 2Biochemical measurements in groups A and B after vitamin D supplementationGroup AGroup B*P* value3 months (June) 25(OH)D (ng/ml)10.8 ± 7.231.6 ± 15.5\<0.001 PTH (pg/ml)43 ± 2238 ± 160.356 Serum calcium (mg/dl)9.01 ± 0.649.14 ± 0.380.389 months (December) 25(OH)D (ng/ml)22.4 ± 12.430.7 ± 12.8\<0.001 PTH (pg/ml)21 ± 919 ± 80.480 Serum calcium (mg/dl)9.46 ± 0.409.50 ± 0.350.375

Interesting biochemical responses were seen after 6 months of cholecalciferol supplementation with 60,000 IU/month (group A) vs. 120,000 IU/month (group B). In low-dose group A, 25(OH)D levels increased from 10.8 ± 7.2 to 22.4 ± 12.4 ng/ml (*P* \< 0.001) during the winter months. This increase was less as compared to that achieved in group B with the same dose for 3 months during the summer (4.8 ± 3.5 to 31.6 ± 15.5 ng/ml; Fig. [2a](#Fig2){ref-type="fig"}). This finding emphasizes the winter effect on the 25(OH)D levels. Serum 25(OH)D levels have been shown to fall to undetectable levels in Asian Indians during winters in previous studies \[[@CR21]\]. During winter, sunlight is less effective in raising the 25(OH)D levels and levels tend to decline.

A similar effect of season on response to vitamin D supplementation was seen in group B as well. The initial increase in 25(OH)D levels observed at 3 months (summer) with vitamin D supplementation of 60,000 IU/month \[4.8 ± 3.5 ng/ml (March) to 31.6 ± 15.5 ng/ml (June)\] did not continue at 9 months (winter) \[30.7 ± 12.8 ng/ml\], despite an increase in the dose to 120,000 IU/month. However, there was no decline and the initial 25(OH)D levels achieved were maintained. Figure [2a](#Fig2){ref-type="fig"} shows this plateau in 25(OH)D levels. Thus, a drop in 25(OH)D levels during winter in group B was prevented but at a dose which was double of that used during summer. Therefore, our study confirms the need for higher doses of vitamin D supplementation during winter.

Our study also reconfirms the finding that the average increment in serum 25(OH)D levels is inversely proportional to the baseline 25(OH)D levels \[[@CR19]\]. The same dose of 50 μg/day produced different increments in groups A and B. The average increment produced in group B (0.5 ng/ml for every microgram of cholecalciferol administered orally) at 3 months was similar to that reported earlier \[[@CR13], [@CR19], [@CR25]\]. However, the increment in group A (0.2 ng/ml/μg) at 9 months was less with the same dose. In addition to the winter effect, this can be attributed to the higher baseline 25(OH)D level in group A \[[@CR13]\].

The increment in 25(OH)D levels although less was seen in group A with 60,000 IU/month but was not seen at all in group B with 120,000 IU/month during winter months. Again, this can be explained on the basis of the differences in the baseline 25(OH)D levels in the two groups at 3 months. It has been reported that the average increment in 25(OH)D levels is 0.3 ng/ml or less if the baseline 25(OH)D level is \>28 ng/ml \[[@CR19]\]. The baseline 25(OH)D level in group B at 3 months was 31.6 ng/ml, which explains for no increment response observed in this group. In group A, the baseline 25(OH)D level at 3 months was 10.8 ng/ml, much less than the optimal levels. This is clearly demonstrated in Fig. [2a](#Fig2){ref-type="fig"}. Other studies have also implied that plateau levels of 25(OH)D can occur within 5 months \[[@CR20], [@CR26]\].

Higher levels of 25(OH)D generally correlate with lower concentration of PTH \[[@CR26]\]. The present data confirm that both doses of supplementation produced a significant suppression of PTH, to about half of the baseline levels (Fig. [2b](#Fig2){ref-type="fig"}). Lack of statistical significance in PTH between the dose groups could be attributed to relatively small sample sizes in this study (Table [2](#Tab2){ref-type="table"}).

Serum calcium had increased in both groups at 9 months, but the levels remained within the normal range. There was no evidence of hypercalciuria as a result of long-term use of vitamin D at a relatively high dose of either 60,000 IU/month (2,000 IU/day) or 120,000 IU/month (4,000 IU/day). This dose was similar to that required to achieve optimal 25(OH)D levels in Caucasians \[[@CR16]\]. According to Aloia et al., vitamin D dose of 95 µg/day (3,800 IU) for those above a 25(OH)D threshold of 22 ng/ml and a dose of 125 µg/day (5,000 IU) for those below that threshold is required to achieve 25(OH)D concentration of \>30 ng/ml. Since our study subjects had very low baseline 25(OH)D levels with very limited sunlight exposure, the use of higher doses was justified.

Our results showed that daily intake of 50 μg (2,000 IU) of vitamin D (cholecalciferol) during summers would bring serum 25(OH)D levels to the vitamin D-sufficient range in most of the subjects at 3 months. This dose is presently considered to be the safe upper limit of vitamin D intake \[[@CR14]\]. Our study also showed that in order to maintain optimal vitamin D levels in winters, even higher doses of 100 μg (4,000 IU/day) are required. The 50-µg/day dosage was effective at ensuring 25(OH)D concentrations of ≥20 ng/ml in 70% subjects during summer. The 100-µg/day dosage was effective at ensuring 25(OH)D concentrations of ≥20 ng/ml in 81.8% of the same subjects during winter, similar to that reported by Veith et al. \[[@CR22]\]. Our results are similar to those of other studies showing higher 25(OH)D levels with 4,000 IU of oral vitamin D per day with no risk of hypercalcemia or hypercalciuria \[[@CR20], [@CR22], [@CR27]\].

Conclusion {#Sec13}
==========

Our study confirms the high prevalence of hypovitaminosis D in apparently healthy Indian women and shows that in a tropical country like India, monthly oral administration of 60,000 IU cholecalciferol (\~2,000 IU/day or 50 μg/day) is effective in raising serum 25(OH)D to desired levels(\>30 ng/ml) during summer. However, higher doses of cholecalciferol---120,000 IU/month administered orally (\~4,000 IU/day or 100 μg/day)---may be more appropriate during winter. This may be an effective public health strategy in severely deficient countries like India.
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